Logo image of POM

POMDOCTOR LTD - ADR (POM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:POM - US73181R1086 - ADR

0.3259 USD
+0.03 (+10.51%)
Last: 1/2/2026, 8:00:01 PM
0.315 USD
-0.01 (-3.34%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to POM. POM was compared to 101 industry peers in the Health Care Providers & Services industry. POM has a bad profitability rating. Also its financial health evaluation is rather negative. POM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

POM had negative earnings in the past year.
In the past year POM has reported a negative cash flow from operations.
POM Yearly Net Income VS EBIT VS OCF VS FCFPOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of POM (-310.12%) is worse than 95.05% of its industry peers.
Industry RankSector Rank
ROA -310.12%
ROE N/A
ROIC N/A
ROA(3y)-262.51%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POM Yearly ROA, ROE, ROICPOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -100 -200 -300

1.3 Margins

With a Gross Margin value of 13.92%, POM is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
The Profit Margin and Operating Margin are not available for POM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
POM Yearly Profit, Operating, Gross MarginsPOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 20 -20 -40

More info and screens

0

2. Health

2.1 Basic Checks

POM does not have a ROIC to compare to the WACC, probably because it is not profitable.
POM has a worse debt/assets ratio than last year.
POM Yearly Shares OutstandingPOM Yearly Shares OutstandingYearly Shares Outstanding 2023
POM Yearly Total Debt VS Total AssetsPOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

POM has an Altman-Z score of -66.29. This is a bad value and indicates that POM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of POM (-66.29) is worse than 93.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -66.29
ROIC/WACCN/A
WACC4.76%
POM Yearly LT Debt VS Equity VS FCFPOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M -200M -400M -600M

2.3 Liquidity

A Current Ratio of 0.21 indicates that POM may have some problems paying its short term obligations.
POM has a worse Current ratio (0.21) than 93.07% of its industry peers.
A Quick Ratio of 0.15 indicates that POM may have some problems paying its short term obligations.
With a Quick ratio value of 0.15, POM is not doing good in the industry: 92.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.15
POM Yearly Current Assets VS Current LiabilitesPOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

POM shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.40%.
POM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.37%.
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.4%
Revenue 1Y (TTM)12.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.37%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
POM Yearly Revenue VS EstimatesPOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100M 200M 300M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

POM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
POM Price Earnings VS Forward Price EarningsPOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POM Per share dataPOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

POM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

POMDOCTOR LTD - ADR

NASDAQ:POM (1/2/2026, 8:00:01 PM)

After market: 0.315 -0.01 (-3.34%)

0.3259

+0.03 (+10.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap38.60M
Revenue(TTM)342.56M
Net Income(TTM)-143.36M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.79
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.41
BVpS-0.81
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -310.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.92%
FCFM N/A
ROA(3y)-262.51%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover7.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.1%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.15
Altman-Z -66.29
F-Score3
WACC4.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.78%
OCF growth 3YN/A
OCF growth 5YN/A

POMDOCTOR LTD - ADR / POM FAQ

Can you provide the ChartMill fundamental rating for POMDOCTOR LTD - ADR?

ChartMill assigns a fundamental rating of 0 / 10 to POM.


What is the valuation status of POMDOCTOR LTD - ADR (POM) stock?

ChartMill assigns a valuation rating of 0 / 10 to POMDOCTOR LTD - ADR (POM). This can be considered as Overvalued.


How profitable is POMDOCTOR LTD - ADR (POM) stock?

POMDOCTOR LTD - ADR (POM) has a profitability rating of 0 / 10.